Literature DB >> 22076323

Epidermal proteases in the pathogenesis of rosacea.

Ulf Meyer-Hoffert1, Jens-Michael Schröder.   

Abstract

A number of different proteases and their inhibitors have a role in skin physiology and in the pathophysiology of inflammatory skin diseases. Proteases are important in the desquamation process and orderly regulation of the skin's barrier function. On the basis of the catalytic domain, proteases are classified into aspartate-, cysteine-, glutamate-, metallo-, serine-, and threonine proteases. Particularly, serine proteases (SPs) contribute to epidermal permeability barrier homeostasis, as acute barrier disruption increases SP activity in skin and inhibition by topical SP inhibitors accelerated recovery of barrier function after acute abrogation. In rosacea, increased levels of the vasoactive and inflammatory host-defense peptide cathelicidin LL-37 and its proteolytic peptide fragments were found, which were explained by an abnormal production of tryptic activity originating from kallikrein-related peptidase (KLK) 5. It is therefore possible that also other proteases, even from microbial or parasite origin, have a role in rosacea by forming alternate angiogenic and proinflammatory cathelicidin peptides. Further, the regulation of protease activity, in particular KLK-5 activity, might have a role in rosacea. This review briefly summarizes our current knowledge about keratinocyte-derived proteases and protease inhibitors, which might have a role in the pathophysiology of rosacea.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22076323     DOI: 10.1038/jidsymp.2011.2

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  27 in total

Review 1.  Clinical, cellular, and molecular aspects in the pathophysiology of rosacea.

Authors:  Martin Steinhoff; Jörg Buddenkotte; Jerome Aubert; Mathias Sulk; Pawel Novak; Verena D Schwab; Christian Mess; Ferda Cevikbas; Michel Rivier; Isabelle Carlavan; Sophie Déret; Carine Rosignoli; Dieter Metze; Thomas A Luger; Johannes J Voegel
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

Review 2.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

3.  Application of protease technology in dermatology: rationale for incorporation into skin care with initial observations on formulations designed for skin cleansing, maintenance of hydration, and restoration of the epidermal permeability barrier.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-06

Review 4.  Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit.

Authors:  Aimee M Two; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2014-01

5.  Expression of human skin-specific genes defined by transcriptomics and antibody-based profiling.

Authors:  Per-Henrik D Edqvist; Linn Fagerberg; Björn M Hallström; Angelika Danielsson; Karolina Edlund; Mathias Uhlén; Fredrik Pontén
Journal:  J Histochem Cytochem       Date:  2014-11-19       Impact factor: 2.479

Review 6.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

7.  Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury.

Authors:  Jan Fischer; Zhihong Wu; Tomasz Kantyka; Maria Sperrhacke; Olga Dimitrieva; Yulia Koblyakova; Kerstin Ahrens; Nina Graumann; Hansjörg Baurecht; Karina Reiss; Jens-Michael Schröder; Ehrhardt Proksch; Ulf Meyer-Hoffert
Journal:  J Invest Dermatol       Date:  2013-11-22       Impact factor: 8.551

Review 8.  Skin barrier in rosacea.

Authors:  Flavia Alvim Sant'Anna Addor
Journal:  An Bras Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.896

9.  Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

Review 10.  Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features.

Authors:  Giuseppe Micali; Peter Arne Gerber; Francesco Lacarrubba; Gregor Schäfer
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.